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Abstract: Pseudonocardians A–C (2–4), three new diazaanthraquinone derivatives, along 
with a previously synthesized compound deoxynyboquinone (1), were produced by the 
strain SCSIO 01299, a marine actinomycete member of the genus Pseudonocardia, isolated 
from deep-sea sediment of the South China Sea. The structures of compounds 1–4 were 
determined by mass spectrometry and NMR experiments (
1H, 
13C, HSQC, and HMBC). 
The structure of compound 1, which was obtained for the first time from a natural source, 
was confirmed by X-ray analysis. Compounds 1–3 exhibited potent cytotoxic activities 
against three tumor cell lines of SF-268, MCF-7 and NCI-H460 with IC50 values between 
0.01 and 0.21 μM,  and also showed  antibacterial activities on Staphylococcus aureus 
ATCC 29213, Enterococcus faecalis ATCC 29212 and Bacillus thuringensis SCSIO BT01, 
with MIC values of 1–4 μg mL
−1. 
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1. Introduction 
Marine microorganisms, especially marine actinomycetes, are continuing to be rich sources of 
bioactive metabolites, with 273 new compounds reported from marine microbes in 2009 [1]. Natural 
products derived from marine actinomycetes displayed a wide range of bioactivities, such as  
antitumor [2,3], antiinfective [4], and antimalarial [5]. In recent years, South China Sea has been 
emerging as a potentially abundant source of novel species/genera of marine actinomycetes [6–10]. 
Some new bioactive compounds, such as marinactinones A–C [10], lobophorins E and F [11], were 
reported from marine actinomycetes isolated from the South China Sea. 
In our continuous search for bioactive secondary metabolites from South China Sea-derived 
actinomycetes, crude extracts of the strain SCSIO 01299 were found to exhibit significant cytotoxic 
and antibacterial activities. Upon large fermentation of the strain SCSIO 01299, four products (1–4) 
were isolated and the main product 1 showed UV absorptions at 276, 354, 461 nm, characteristic of a 
highly conjugated chromophore related to anthraquinone compounds [12]. Herein we report the 
preliminary characterization of the strain SCSIO 01299 as a member of the genus Pseudonocardia by 
16S rRNA gene sequence analysis, the isolation and structural elucidation of four diazaanthraquinone 
derivatives including a previously synthesized compound deoxynyboquinone (DNQ, 1) and three new 
analogues, pseudonocardians A–C (2–4). In addition, antibacterial and cytotoxic activities for 
compounds 1–4 were investigated. 
2. Results and Discussion 
2.1. Taxonomy of the Producing Strain 
The strain SCSIO 01299 was isolated from deep-sea sediment (−3258 m) of the South China Sea, 
and was preliminarily identified as an actinomycetal species based on morphology observation. The 
16S rRNA gene of the strain SCSIO 01299 was PCR amplified, sequenced and submitted to GenBank 
(accession number is JN204514). BLAST results showed that the new isolate had the highest similarity 
(98%) with Pseudonocardia autotrophica IMSNU 20050
T [13]. The phylogenetic tree generated by a 
neighbor-joining method clearly revealed the evolutionary relationship of the strain SCSIO 01299 to a 
group of Pseudonocardia species (Figure 1). Thus, this strain was designated Pseudonocardia sp. 
SCSIO 01299. 
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Figure 1. Phylogenetic dendrogram of the strain SCSIO 01299 and its closest relatives 
reconstructed by the neighbor-joining method based on 16S rRNA gene sequences. 
 
2.2. Structural Elucidation 
Compound 1 was obtained as red needles. It gave a [M + H]
+ at m/z 285.0 and a [M − H]
− at  
m/z 283.2 in the ESI-MS, indicating a molecular weight of 284.0. The 
1H and 
13C NMR spectra of 1 
displayed 15 carbon signals, including two methyl doublets [δH 2.55 (3H, d, J = 1.0 Hz, Me-17), 2.59 
(3H, d, J = 1.0 Hz, Me-16); δC 22.1 (q, Me-17), 23.0 (q, Me-16)] and one methyl singlet [δH 4.01 (3H, s, 
Me-15);  δC 33.9 (q, Me-15)], two sp
2 methines [δH 6.78 (1H, d, J  = 1.0 Hz, H-7), 6.82 (1H, d,  
J = 1.0 Hz, H-3); δC 126.8 (d, C-3) and 127.1 (d, C-7)], and 10 sp
2 quarternary carbons with four from 
carbonyls [δC 161.4 (s), 162.4 (s), 182.4 (s), and 176.9 (s)] (Table 1). The structure of ring A in 1 was 
constructed based on HMBC correlations of the methyl H3-15 to C-2/C-11, the methyl H3-16 to 
C-3/C-4/C-12, and H-3 to C-2/C-12/C-16. The structure of ring B was deduced from HMBC 
correlations of H-7 to C-8/C-13/C-17 and H3-17 to C-6/C-7/C-13. These two moieties were then 
connected through two carbonyls [δC 182.4 and 176.9]. Finally, 1 was unambiguously identified to  
be deoxynyboquinone (DNQ, Figures 2 and 3), a chemically synthesized compound [14,15], by X-ray 
crystallographic analysis. 
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Table 1. 
1H and 
13C NMR spectroscopic data of compounds 1–3. 
No. 
1 
a 2 
b 2 
c 3 
b 
δH (J in Hz)  δC  δH (J in Hz)  δC  δH (J in Hz)  δC  δH (J in Hz)  δC 
2    161.4 s    164.5 s    161.0 s    164.5 s 
3  6.82 d (1.0)  126.8 d  6.48, s  121.4 d 6.39, d (1.0)  119.8 d  6.49, d (1.0)  121.4 d
4    149.0 s    153.5s    150.6 s    153.5 s 
5    182.4 s *    183.5 s    181.9 s    183.6 s 
6    150.5 s    153.8 s    150.1 s    153.6 s 
7  6.78 d (1.0)  127.1 d  6.32, s  122.6 d 6.24, d (1.0)  121.2 d  6.30, d (1.0)  122.6 d
8    162.4 s    162.8 s    159.3 s    163.0 s 
10    176.9 s *    72.7 s    70.8 s    72.8 s 
11    141.4 s    151.8 s    149.9 s    152.0 s 
12    118.2 s    117.8 s    114.7 s    117.8 s 
13    114.9 s    110.8 s    107.8 s    111.0 s 
14    141.7 s    157.0 s    155.8 s    156.9 s 
15  4.01, s  33.9 q  3.90, s  34.1 q  3.71, s  32.6 q  3.90, s  34.2 q 
16  2.59, d (1.0)  23.0 q  2.57, s  23.6 q  2.44, d (1.0)  22.7 q  2.55, d, (1.0)  23.5 q 
17  2.55, d (1.0)  22.1 q  2.58, s  21.3 q  2.45, d (1.0)  20.5 q  2.59, d (1.0)  21.3 q 
18      2.71, d (13.5), 
3.30, d (13.5) 
52.4 t  2.62, d (13.5), 
3.13, d (13.5) 
50.8 t  2.51, d (13.8),   
3.41, d (13.8) 
47.9 t 
19       97.6 s    95.5 s    100.8 s 
20      2.19, s  26.5 q  2.03, s  25.9 q  2.41, dd (7.5, 14.0), 
2.84, dd (7.5, 14.0) 
31.6 t 
21              1.22, t (7.5)  9.3 q 
* Exchangeable. 
a Measured in pyridine-d5; 
b Measured in CD3OD; 
c Measured in DMSO-d6. 500 MHz for 
1H NMR; 125 MHz for 
13C NMR. 
Compound 2, designated pseudonocardian A, was isolated as a white solid. The molecular formula 
of compound 2 was established as C18H18N2O5 (m/z 343.1305, calculated for 343.1294 [M + H]
+), 
indicating 11 degrees of unsaturation. The 
1H and 
13C NMR spectra of compound 2 were similar to 
those of 1, except that the C-10 carbonyl in 1 was absent in 2. Instead, more modifications on C-10 
were found in 2, including two oxygenated quaternary carbons [δC 72.7 (s, C-10), 97.6 (s, C-19)], a 
methylene [δH 2.71 (d, J = 13.5 Hz, H-18), 3.30 (d, J = 13.5 Hz, H-18), δC 52.4 (t, C-18)] and a methyl 
singlet [δH 2.19 (s, Me-20), δC 26.5 (q, Me-20)]. Taking the unsaturation degrees into consideration, 
there should be an additional ring in 2. Based on the HMBC correlations of H-18 to 
C-10/C-11/C-14/C-19, and of H-20 to C-18/C-19 (Figure 4A), C-19 was supposed to be connected to 
N-9. The assumption was confirmed by the downfield shift of C-19 at δC 97.6. After careful analysis of 
HMBC correlations, the planar structure of 2 was established (Figure 2). In order to assign the relative 
configuration of 2, a NOESY experiment was carried out in DMSO-d6. NOESY correlation of OH-10 
to H3-20 was found (Figure 4B), indicating the two hydroxyls (OH-10 and OH-19) were on the 
opposite sides. This was consistent with the mimic configuration using the MM2 minimum energy 
calculation by ChemBio3D Ultra 11.0 (Figure 4B). Therefore, the relative configuration of compound 2 
was shown in Figure 2. 
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Figure 2. Chemical structures of compounds 1–4. 
 
Figure 3. X-ray analysis of compound 1. 
 
Figure 4. Two dimensional NMR characterizations of compound 2: (A) Selected HMBC 
correlations; (B) Key NOESY correlation and mimic structure of 2, using the MM2 
minimum energy calculation by ChemBio3D Ultra 11.0. 
 
A B 
Compound 3, designated pseudonocardian B, was obtained as white solid. Its molecular formula 
was assigned as C19H20N2O5 based on the HR-MS data (m/z  357.1456, calculated for 357.1450,  
[M + H]
+). Comparing the 
1H and 
13C NMR spectroscopic data of 3 with 2, the only difference was 
that the C-19 methyl singlet in 2 was substituted by an ethyl group [δH 1.22 (t, J = 7.5 Hz, Me-21), 
2.41 (dd, J = 7.5, 14.0 Hz, H-20a), 2.84 (dd, J = 7.5, 14.0 Hz, H-20b), δC 9.3 (q, Me-21), 31.6 (t, C-20)] Mar. Drugs 2011, 9  
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in 3 (Table 1). This substitution was confirmed by HMBC correlations of H-21 to C-19/C-20 and of 
H-20 to C-18/C-19/C-21. Therefore, the structure of 3 was established as shown in Figure 2. 
Compound 4, designated pseudonocardian C, was isolated as a red brown powder. The molecular 
formula of 4 was established as C21H24N2O8 by HR-MS (m/z  433.1609, calculated for 433.1611  
[M + H]
+). In comparison of the 
1H and 
13C NMR spectroscopic data of 4 and 1, signals for both ring A 
[δH 6.57 (s, H-3), δC 166.0 (s, C-2), 151.4 (s, C-2), 137.3 (s, C-11), 120.8 (d, C-3), 118.7 (s, C-12)] and 
ring B [δH 6.54 (s, H-7), δC 164.9 (s, C-8), 149.4 (s, C-6), 135.1 (s, C-14), 120.4 (d, C-7), 120.4  
(s, C-13)] were found in 4. However, the two ketone groups (C-5 and C-10) in 1 were displaced in 4 by 
a sp
2 methine singlet [δH 8.01 (s, H-5), δC 119.7 (d, C-5)], an oxygenated sp
2 quaternary carbon signals 
[δC 132.1 (s, C-10)], and a β-glucose moiety with coupling constant J1′,2′ of 8.0 Hz [16]: [δH 4.57 (1H, 
d, J = 8.0 Hz, H-1′), 3.66 (1H, m, H-2′), 3.44 (1H, m, H-3′), 3.46 (1H, m, H-4′), 3.13 (m, H-5′),  
3.73 (1H, dd, J = 2.3, 11.8 Hz, H-6a′), 3.68 (1H, dd, J = 5.0, 11.8 Hz, H-6b′); δC 107.8 (d, C-1′),  
75.5 (d, C-2′), 78.0 (d, C-3′), 70.9 (d, C-4′), 78.7 (d, C-5′), 62.3 (t, C-6′)]. The HMBC correlation from 
H-5 to C-4/C-6/C-11/C-14 indicated that moiety A and moiety B were connected by a benzene ring. 
And the HMBC correlation from H-1 to C-10 showed that the glucose was located at C-10. On these 
bases of these cumulative evidences, the structure of 4 was established as shown in Figure 2. 
2.3. Biological Activities 
Compounds  1–4 were evaluated for their antibacterial activities against Staphylococcus aureus 
ATCC 29213, Enterococcus faecalis ATCC 29212 and Bacillus thuringensis SCSIO BT01, and  
in vitro cytotoxic activities against three human tumor cell lines, including SF-268 (human glioma cell 
line), MCF-7 (human breast adenocarcinoma cell line) and NCI-H460 (human non-small cell lung 
cancer cell line) (Table 2). Compounds 1–3 showed strong antibacterial activities towards all three 
assayed indicators with MIC values ranging from 1–4 µg mL
−1. Pseudonocardian A (2), bearing a 
methyl group at C-19, displayed one-fold less antibacterial activities than pseudonocardian B (3), 
which contained an ethyl group at C-19. DNQ (1), pseudonocardians A (2) and B (3) exhibited nearly 
the same potency against tumor cell lines SF-268 and MCF-7 with IC50 values in the range of  
15–28 nM (Table 2). DNQ (1) showed a slightly better activity than pseudonocardians A (2) and B (3) 
against NCI-H460 (Table 2). Pseudonocardian C (4) showed no antibacterial activity, while preserved 
certain in vitro cytotoxic activities comparable to those of the control compound cisplatin. However, 
its cytotoxicities were largely reduced when compared to 1–3 (Table 2). 
Table 2. Antibacterial and cytotoxic activities of compounds 1–4. 
Compounds 
MIC (μg mL
−1)   IC50 (μM) 
B. thuringensis 
SCSIO BT01 
S. aureus 
ATCC 29213 
E. faecalis 
ATCC 29212 
  SF-268 MCF-7 NCI-H460 
1  1 1  1    0.022  0.015  0.080 
2  4 4  2    0.028  0.027  0.209 
3  2 2  2    0.022  0.021  0.177 
4  >128 >128  >128    6.70  8.02  43.28 
Cisplatin  ND 
a ND 
a ND 
a   3.99  9.24  1.53 
a Not detected. Mar. Drugs 2011, 9  
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2.4. Discussion 
Diazaanthraquinones comprise a class of natural products, either naturally-occurring [17–22], or 
chemically synthesized [23–30], both of them exhibited good antitumor or antibacterial activities, 
highlighting their potential for drug development. Deoxynyboquinone (DNQ, 1), a diazaanthraquinone, 
was originally synthesized during nybomycin structural studies [14]. Recently, a facile synthetic route 
for DNQ (1) was reported [15]. Studies on biological activity and mechanism of action revealed that 
DNQ (1) rivaled doxorubicin for the potency in tumor cell culture and was even effective against  
a doxorubincin-resistant cell line, with a mechanism of inducing cell death through generation of 
reactive oxygen species (ROS) [15]. 
In this study, we reported the isolation of DNQ (1) for the first time from a natural source, the 
marine actinomycete Pseudonocardia sp. SCSIO 01299. In addition, we confirmed the structure of 
DNQ (1) by X-ray crystallographic analysis for the first time. More interestingly, we isolated 3 novel 
DNQ (1) analogues, pseudonocardians A–C (2–4), from the same strain. Consistent with previous 
report [15], DNQ (1) exhibited potent in vitro cytotoxic activities against three tumor cell lines of 
SF-268, MCF-7 and NCI-H460, with IC50 values of 22, 15, and 80 nM, respectively. Pesudonocardians 
A (2) and B (3) had almost the same in vitro cytotoxic activities as those of DNQ (1), with the  
added benefit of being ~10-fold more aqueously soluble than 1. Pseudonocardian C (4), although 
being >300-fold less potent than 1–3, showed comparable cytotoxicity to the positive control cisplatin 
(Table 2). Unlike 1–3, pseudonocardian C (4) displayed no observable antibacterial activities, probably 
due to the glucosylation at C-10, which resembled the inactivation of macrolide antibiotics by 
glycosylation as a resistance mechanism [31].   
3. Experimental Section 
3.1. General Experimental Procedures 
Materials for column chromatography (CC) were silica gel (100–200 mesh; 300–400 mesh; 
Jiangyou Silica Gel Development, Inc., Yantai, China), Sephadex LH-20 (40–70 μm; Amersham 
Pharmacia Biotech AB, Uppsala, Sweden), and YMC-GEL ODS-A (12 nm S-50 μm; Japan). Thin 
layer chromatography (TLC, 0.1–0.2 mm or 0.3–0.4 mm) was conducted with precoated glass plates 
(silica gel GF254, 10–40 nm, Jiangyou Silica Gel Development, Inc., Yantai, China). Medium pressure 
liquid chromatography (MPLC) was performed on automatic flash chromatography (EZ Purifier III, 
Leisure Science Co., Ltd. Shanghai, China) with monitor wavelength of 234 nm and collector 
wavelength of 300 nm. Mass spectral data were obtained on a quadrupole-time-of-flight mass 
spectrometry (Waters, Milford, MA, USA) for high resolution fast atom bombardment mass 
spectrometry (HRFABMS). The optical rotation was recorded on a 341 polarimeter (Perkin Elmer, Inc., 
Norwalk, CT, USA). 
1H, 
13C NMR and 2D NMR spectra were recorded on a Bruker AV-500 MHz 
NMR spectrometer (Bruker Biospin GmbH, Rheinstetten, Germany) with tetramethylsilane (TMS,  
δ 0.0 ppm) as the internal standard. 
1H NMR data were reported as chemical shift (multiplicity [singlet (s), 
doublet (d), triplet (t), and multiplet (m)], and coupling constants (Hz); 
13C NMR data were reported as 
follows: chemical shift [quaternary carbon (s), methine (d), methylene (t), methyl (q)]. Deuterated 
NMR solvents were purchased from Cambridge Isotopes (Andover, MA, USA). Mar. Drugs 2011, 9  
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3.2. Microbiological Material 
The strain SCSIO 01299 was isolated from a sediment sample (E 120°0.975′, N 19°0.664′) at the 
depth of 3258 m collected from an open voyage to the South China Sea in August 2007, and was 
deposited in the type culture collection of Center for Marine Microbiology, Research Network of 
Applied Microbiology, South China Sea Institute of Oceanology, Chinese Academy of Sciences, 
Guangzhou, China. Genomic DNA isolation, PCR amplification of 16S rRNA gene, sequence 
alignment, and phylogenetic tree construction of the strain SCSIO 01299 were performed as described 
previously [6]. A single colony of SCSIO 01299 was inoculated into 50 mL seed medium (soybean 
meal 0.5%, soluble starch 1.5%, peptone bacteriological 1.5%, glycerol 1.5%, CaCO3 0.2%,  
sea salt 3%, pH 7.4, adjusted before sterilization) in 250 mL Erlenmeyer flasks, and was cultured on a 
rotary shaker at 200 r.p.m. and 28 °C for 2 days. 10% inoculums were transferred into 50 mL 
production medium (the same as the seed medium) in 250 mL Erlenmeyer flasks, and were 
subsequently incubated on a rotary shaker at 200 r.p.m., 28 °C for 5 days. 
3.3. Extraction and Isolation 
The fermentation broth (9 L) was extracted with equal volume of butanone for 4 times to afford the 
residue A after evaporation. The mycelia cake was extracted 3 times with 6 L acetone. After removing 
acetone, the residue was re-extracted by 6 L butanone to afford the residue B upon removal of the 
solvent under vacuum. Residues A and B were combined and subjected to column chromatography 
(CC) over silica gel (300–400 mesh, 150 g), eluting with a gradient of CHCl3/CH3OH (100:0→0:100) 
to give three fractions (Fr.1–Fr.3). Compound 1 (150.3 mg, 16.7 mg L
−1) was obtained from fraction 
Fr.1 after elution with CHCl3/CH3OH (1:1) on Sephadex LH-20 and repeated recrystallization in 
CHCl3/CH3OH (10:1). Fraction Fr.2 was subjected to Sephadex LH-20 column chromatography, 
eluting with CHCl3/CH3OH (1:1), and then further chromatographed on silica gel (300–400 mesh, 40 g), 
eluting with CHCl3/CH3OH (20:1). Final purification was conducted by C18 reverse phase MPLC 
(20 × 2.5 cm ID), eluting with a linear gradient of CH3OH/H2O (0%→55%, 15 mL min
−1, 100 min), to 
afford 2 (15.8 mg, 1.76 mg L
−1) and 3 (12.5 mg, 1.39 mg L
−1). Similarly, 4 (6.6 mg, 0.73 mg L
−1) was 
obtained from Fr.4 after column chromatography on Sephadex LH-20 (CHCl3/CH3OH, 1:1) and 
further purification by RP-MPLC. 
3.4. Characterization Data 
Deoxynyboquinone (1). Red needles, UV (CH3CN/H2O/TFA)  λmax: 276, 354, 461 nm. 
1H and 
13C  NMR data, see Table 1; ESIMS m/z  285.0 [M + H]
+, 569.7 [2M + H]
+, 283.2 [M − H]
−,  
567.4 [2M − H]
−. 
Crystal data for deoxynyboquinone (1) [32]: Red triclinic crystal of C15H12N2O4. Space group P-1,  
a = 4.8353 (10) Å, α = 85.195(4)°; b = 9.373(2) Å, β = 89.350(5)°; c = 13.780 (3) Å, γ = 82.094(4)°;  
V = 616.5 (2) Å
3, Z = 2; crystal size 0.301 × 0.126 × 0.057 mm
3. A total of 3289 unique reflections  
(θ = 2.20–25.49°) were collected using graphite monochromated Mo Kα (λ = 0.71073 Å) on a CCD 
area detector diffractometer. The structure was solved by direct methods (SHELXS-97) and expanded 
using Fourier techniques (SHELXS-97). The final cycle of full-matrix least-squares refinement  Mar. Drugs 2011, 9  
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was based on 2273 data, 0 restraints and 198 variable parameters. Final R indicates R1 = 0.0690,  
wR2 = 0.1725 [I > 2σ(I)].  
Pseudonocardian A (2). White solid, [α]
20 
D  +1.52° (c 0.46, MeOH), UV (CH3CN/H2O/TFA) λmax: 
235, 300 nm. 
1H and 
13C NMR data, see Table 1. HRESI-MS [M + H]
+  m/z  343.1305  
(calcd. for C18H19N2O5 343.1294), ESIMS: m/z 343.2 [M + H]
+, 685.4 [2M + Na]
+, 341.1 [M − H]
−, 
683.3 [2M − H]
−. 
Pseudonocardian B (3). White solid, [α]
20 
D   −1.56° (c 0.90, MeOH), UV (CH3CN/H2O/TFA) λmax: 
235, 300 nm. 
1H and 
13C NMR data, see Table 1. HRESI-MS: m/z [M + H]
+ 357.1456 (calcd. for 
C19H21N2O5, 357.1450); ESIMS: m/z 357.2 [M + H]
+, 379.3 [M + Na]
+, 735.3 [2M + Na]
+,  
355.2 [M − H]
−, 711.0 [2M − H]
−. 
Pseudonocardian C (4). Red brown powder, [α]
25 
D   −25.6° (c 0.16, MeOH), UV (CH3CN/H2O/TFA) 
λmax: 236, 264, 352, 368 nm. 
1H NMR (500 MHz, CD3OD): 8.01 (1H, s, H-5), 6.57 (1H, s, H-3), 6.54 
(1H, s, H-7), 4.57 (1H, d, J = 8.0 Hz, H-1′), 3.96 (1H, s, H-15), 3.73 (1H, dd, J = 2.3, 11.8 Hz, H-6′a), 
3.68 (1H, dd, J = 5.0, 11.8 Hz, H-6′b), 3.66 (1H, m, H-2′), 3.46 (1H, m, H-4′), 3.44 (1H, m, H-3′), 3.13 
(1H, m, H-5′), 2.63 (1H, s, H-16), 2.60 (1H, s, H-17); and 
13C NMR (125 MHz, CD3OD): 166.0 (s, 
C-2), 164.9 (s, C-8), 151.4 (s, C-6), 149.4 (s, C-4), 137.3 (s, C-11), 135.1 (s, C-14), 132.1 (s, C-10), 
120.8 (d, C-3), 120.4 (d, C-7), 120.4 (s, C-13), 119.7 (d, C-5), 118.7 (s, C-12), 107.8 (d, C-1′),  
78.7 (d, C-5′), 78.0 (d, C-3′), 75.5 (d, C-2′), 70.9 (d, C-4′), 62.3 (t, C-6′), 37.4 (q, Me-15),  
19.3 (q, Me-17), 19.0 (q, Me-16). HRESI-MS m/z  433.1609 [M + H]
+ (calcd. for C21H25N2O8,  
[M + H]
+ 433.1611); ESIMS m/z 433.2 [M + H]
+, 455.4 [M + Na]
+, 887.2 [2M + Na]
+, 431.3 [M − H]
−,  
467.2 [M + Cl]
−, 863.3 [2M − H]
−. 
3.5. Antibacterial and Cytotoxic Assay 
Minimal Inhibition Concentration (MIC) values of deoxynyboquinone (1) and pseudonocardians 
A–C (2–4) were determined against 3 indicators (Staphylococcus aureus ATCC 29213, Enterococcus 
faecalis ATCC29212 and Bacillus thuringiensis SCSIO BT01), according to previously described 
methods [33]. Cytotoxicities of the four compounds were assayed against 3 tumor cell lines, including 
MCF-7 (human breast adenocarcinoma cell line), NCI-H460 (human non-small cell lung cancer cell 
line), and SF-268 (human glioma cell line). Assays were performed as described previously [34].   
4. Conclusions 
We have found that deep-sea actinomycete Pseudonocardia sp. SCSIO 01299 is a natural producer 
of the promising anticancer drug candidate deoxynyboquinone (1) and three diazaanthraquinone 
derivatives pseudonocardians A–C (2–4). In comparison with 1, pseudonocardians A (2) and B (3) 
showed the same anticancer potency but had enhanced aqueous solubility. These findings once again 
highlighted the potential of marine actinomycetes for novel drug discovery. 
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